BIOGEN INC. DL -,0005 | 226.600 / +2.95% |
Date/Time | 01/25 / 20:44 |
Chg. / Chg.(%) | 6.500 / +2.95% |
Bid | - |
Ask | - |
Open | 221.450 |
Previous Close | 220.100 |
High | 226.600 |
Low | 221.450 |
Volume [EUR] | 0.000 |
Volume [Units] | 0 |
Price fixings | 2 |
ISIN | US09062X1037 |
Security | IDP |
Exchange | Stuttgart |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 275.5400 | ![]() |
806,822 |
IEX | 275.29 | ![]() |
45,463 |
Cboe US | 275.44 | ![]() |
34,580 |
London Inter.. | 273.36 | ![]() |
2,334 |
TradeGate | 226.000 | ![]() |
983 |
Xetra | 226.60 | ![]() |
774 |
Vienna Globa.. | 226.60 | ![]() |
114 |
gettex | 226.300 | ![]() |
54 |
Frankfurt | 225.5000 | ![]() |
20 |
München | 221.50 | ![]() |
0 |
Hamburg | 220.65 | ![]() |
0 |
Düsseldorf | 226.35 | ![]() |
0 |
Berlin | 226.70 | ![]() |
0 |
Hannover | 220.65 | ![]() |
0 |
Stuttgart | 226.600 | ![]() |
0 |
Lang & Schwa.. | 223.900 | ![]() |
|
Mexico | 5,375.00 | ![]() |
129 |
News
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/11/2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/08/2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/21/2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
12/17/2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
12/10/2020 / 04:30 - GlobeNewswire